ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1970

Mechanism of Chondroprotective Effects of 4-Methylumbelliferone and 2-Deoxyglucose

Kenya Terabe1, Nobunori Takahashi 1, Yoshifumi Ohashi 2, Toshihisa Kojima 1, Naoki Ishiguro 1, Cheryl Knudson 2 and Warren Knudson 2, 1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2East Carolina University, Greenville

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: chondrocytes, metabolism and glycolysis, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Osteoarthritis & Joint Biology – Basic Science Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: We recently reported that the inhibitor of hyaluronan (HA) biosynthesis, 4-methylumbelliferone (4-MU) blocked IL-1β activation of MMP13 mRNA and protein expression in human osteoarthritic (OA), bovine as well as bovine or OA cartilage explants [1]. This was a somewhat counterintuitive observation because we have also demonstrated that the overexpression of HAS2 (HAS2-OE) exerted the same chondroprotective effects on human and bovine chondrocytes.  Others [2] have reported that HAS2-OE in tumor cells generates a flux in intracellular UDP-sugar pools that resulted in changes in cell metabolism; switching from a dependence on glycolysis to aerobic respiration. HAS2-OE and 4-MU likely also cause dramatic fluxes in intracellular UDP-GlcUA pools. From these results, we hypothesized that the effect of HAS2-OE and 4-MU relate to changing metabolism and the possibility of inhibition of glycolysis induce chondroprotective effect. To determine that, we used the glycolysis inhibitor, 2-Deoxyglucose (2DG) as an alternative agent to change metabolism in chondrocytes.
References:  [1] J. Biol. Chem. 291:12087, 2016; [2] J. Biol. Chem. 291:24105, 2016.

Methods: Bovine and human chondrocyte were stimulated with IL-1β (2ng/ml) in the presence or absence of 4MU (1.0 mM), 2DG (0.2-20 mM). Bovine chondrocytes were tested using Seahorse Flux Analyzer (Agilent Tech) to determine rate changes in medium accumulation of +H protons (indicative of lactic acid accumulation: ECAR) and for O2 consumption (indicative of mitochondrial respiration: OCR). Accumulation of MMP13 and phosphor AMPK (pAMPK) protein was quantified with Western blotting. Human and Bovine cartilage explants were cultured with L-1β in the presence or absence of 2DG (20 mM) for 7 days and stained with Safranin O.

Results: Reduced mitochondrial potential and enhanced dependence on glycolysis was observed in IL-1β stimulated chondrocytes. Co-treatment with 4-MU and 2DG returned the cell metabolism to levels at or below baseline (Fig 1A, B). The Seahorse ATP Rate Assay means the contributions of glycolysis and mitochondrial respiration to chondrocyte ATP production (Fig 1C). In control chondrocytes, the use of glycolysis contributes to the majority of ATP produced (grey bars) approximately 1/5th from the TCA cycle (red bars). IL1β-activated chondrocytes display increase in glycolysis and decrease in mitochondrial contributions. These changes are reversed by co-treatment with 4MU and 2DG. As shown in Figs 2A, 2DG reversed the IL1β-induced increases accumulation of MMP13 protein in human OA chondrocytes by Western blotting analysis. Although IL-1β lost safranin O staining in human and bovine samples, co-incubation with 2DG blocked in the loss of proteoglycan (Fig 2B). pAMPK is associate with energy homeostasis in chondrocytes. IL-1β treatment decreased accumulation of phosphor AMPK. Co-treatment with 4-MU and 2DG resulted in a rescue of the pAMPK status.

Conclusion: 4-MU and 2DG have chondroprotective effect by changing metabolism and upregulate AMPK. We propose that 4MU and 2DG become useful when these endogenous responses are not enough to rescue cells from a pro-catabolic phenotype.

FIGURE 1 Bovine chondrocytes were incubated 24h ± IL1β -2 ng/ml- and without or with 4MU -1.0mM- or 2DG -2.0 mM-. Panel A depicts a representative Mito Stress Test wherein bars represent basal and maximal mitochondrial respiration as a corrected OCR value. Panel B shows
summaries of ECAR data representative of changes in basal glycolysis rates as labeled. Panel C shows a representative ATP rate assay wherein the contribution of glycolysis -grey bars- and mitochondrial respiration -red bars- to ATP production. -**: p<0.01 ***: p<0.001 -

FIGURE 2. Effect of 2DG on chondrocytes activated with IL-β.
Panel A represents the experiment with human OA chondrocytes treated ± 2 ng/ml IL1β in the absence or presence of 0.2, 2.0 or 20 mM 2DG for 24h. Panel B depicts representative examples of bovine and human OA cartilage explants stained by Safranin O.

FIGURE 3. The effect of 4MU and 2DG on p-AMPK changes in IL1β activated chondrocytes. Bovine chondrocytes were treated for 24 h without -Ctr- or with IL1β -2 ng/ml- and ±2DG -2.0 mM-,  ±4MU -0.5 mM-.


Disclosure: K. Terabe, None; N. Takahashi, AbbVie, 8, Asahi Kasei, 8, Astellas, 8, Bristol-Myers Squibb, 8, Chugai, 8, Chugai Pharmaceutical CO.,LTD., 8, Daiichi-Sankyo, 8, Eisai, 8, Eli Lilly, 8, Janssen, 8, Mitsubishi Tanabe, 8, Ono, 8, Pfizer, 8, Takeda, 8, UCB Japan, 8; Y. Ohashi, None; T. Kojima, AbbVie, 2, 8, Abbvie, 8, Astellas, 2, 8, Bristol-Myers Squibb, 2, 8, Chugai, 2, 8, Chugai Pahrmaceutical, 2, 8, Chugai Pharmaceutical CO., LTD., 2, 8, Daiichi-Sankyo, 2, 8, Eli Lilly, 2, 8, Janssen, 2, 8, Janssen Pharmaceutical, 8, Lilly, 2, 8, Mitsubishi Tanabe, 2, 8, Novartis, 2, 8, Pfizer, 2, 8, Takeda, 2, 8, Tanabe Mitsubishi Pharma, 8; N. Ishiguro, AbbVie, 2, 8, Abbvie, 2, 8, Asahi Kasei, 2, 8, Astellas, 2, 8, Astellas Pharma, 2, 8, Bristol-Myers Squibb, 2, 8, Chugai, 2, 8, Chugai Pahrmaceutical, 2, 8, Chugai Pharmaceutical CO.,LTD., 2, 8, Daiichi-Sankyo, 2, 8, Eisai, 2, 8, Eli Lilly, 2, 8, Janssen Pharmaceutical, 8, Kaken, 2, 8, Lilly, 8, Medical Corporation Sanjinkai, 2, 5, 8, Medical Corporation Toukoukai, 2, 5, 8, Mitsubishi Tanabe, 2, 8, Ono, 2, 8, Otsuka, 2, 8, Pfizer, 2, 8, Taisho Toyama, 2, 8, Takeda, 2, 8, Tanabe Mitsubishi Pharma, 2, 8, UCB, 8, Zimmer Biomet, 2, 8; C. Knudson, None; W. Knudson, None.

To cite this abstract in AMA style:

Terabe K, Takahashi N, Ohashi Y, Kojima T, Ishiguro N, Knudson C, Knudson W. Mechanism of Chondroprotective Effects of 4-Methylumbelliferone and 2-Deoxyglucose [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/mechanism-of-chondroprotective-effects-of-4-methylumbelliferone-and-2-deoxyglucose/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mechanism-of-chondroprotective-effects-of-4-methylumbelliferone-and-2-deoxyglucose/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology